H
Helong Zhang
Researcher at Fourth Military Medical University
Publications - 13
Citations - 676
Helong Zhang is an academic researcher from Fourth Military Medical University. The author has contributed to research in topics: Gefitinib & Icotinib. The author has an hindex of 9, co-authored 12 publications receiving 490 citations.
Papers
More filters
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Yi-Long Wu,Ying Cheng,Jianying Zhou,Shun Lu,Yiping Zhang,Jun Zhao,Dong Wan Kim,Ross A. Soo,Sang-We Kim,Hongming Pan,Yuh Min Chen,Chih-Feng Chian,Xiaoqing Liu,Daniel Shao Weng Tan,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,Keunchil Park,James Chih-Hsin Yang,Zhe Liu,Xi Chen,Mengzhao Wang,Shiying Yu,Helong Zhang,Jian Fang,Wei Li,Chih-Hsin Yang,Gee-Chen Chang,Te Chun Hsia,Cheng-Ta Yang,Chin-Chou Wang,Byoung Chul Cho,Ki Hyeong Lee,Young-Chul Kim,Ho Jung An,In Sook Woo,Jae Yong Cho,Sang Won Shin,Jongmin Lee,Joo Hang Kim,Seung Soo Yoo,Terufumi Kato,Naofumi Shinagawa,Shao Weng Daniel Tan,Lynette Si-Mien Ngo,Kananathan Ratnavelu,Azura Rozila Ahmad,Chong-Kin Liam,Filippo de Marinis,Pierfrancesco Tassone,Amelia Insa Molla,Antonio Calles Blanco,Martin Emilio Lazaro Quintela,Enriqueta Felip Font,Anne-Marie C. Dingemans,Lynne Bui +56 more
TL;DR: Survival outcomes were similar between groups, and patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification had acquired resistance to EGFR inhibition, so tepotinib 500 mg was used as the recommended phase 2 dose.
Journal ArticleDOI
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun,Ying Cheng,Xuezhi Hao,Jie Wang,Chengping Hu,Baohui Han,Xiaoqing Liu,Li Zhang,Huiping Wan,Zhongjun Xia,Yunpeng Liu,Wei Li,Mei Hou,Helong Zhang,Qingyu Xiu,Yunzhong Zhu,Jifeng Feng,Shukui Qin,Xiaoyan Luo +18 more
TL;DR: AP therapy demonstrated non-inferiority to EP therapy, prolonging OS for 1.5 months, but this difference was not statistically significant; thus it is proposed as a promising treatment option for ED-SCLC in China.
Journal ArticleDOI
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Feng Bi,Shukui Qin,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Xiufeng Liu,Qiu Meng,Liqing Wu,Feng Chen +17 more
TL;DR: A novel multikinase inhibitor that showed potential benefits in a previous study and is still the standard first-line therapy for advanced hepatocellular carcinoma is presented.
Journal ArticleDOI
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Zhiyong Liang,Ying Cheng,Yuan Chen,Yanping Hu,Wei-ping Liu,You Lu,Jie Wang,Wang Ye,Gang Wu,Jianming Ying,Helong Zhang,Xu-Chao Zhang,Yi-Long Wu +12 more
TL;DR: Though there are several platforms for EGFR mutation detection, highly sensitive platforms for clinical applicability as companion diagnostics for ctDNA based testing are emerging, real-time monitoring of these genetic alterations is mandate for planning treatment strategies.